Management of Osteoporosis with High Fracture Risk
Immediate Pharmacologic Intervention
- The American Academy of Family Physicians recommends initiating pharmacologic treatment immediately with a bisphosphonate as first-line therapy, specifically oral alendronate or risedronate, along with calcium (1000-1200 mg/day) and vitamin D (800 IU/day) supplementation, lifestyle modifications including weight-bearing exercise, smoking cessation, and fall prevention strategies 1, 2
- Oral bisphosphonates (alendronate or risedronate) are strongly recommended as initial therapy because they are well-tolerated, cost-effective, reduce vertebral, non-vertebral, and hip fractures, and clinicians have extensive experience with these agents 3, 4
- Alendronate can be administered as 70 mg weekly or 10 mg daily, while Risedronate can be administered as 35 mg weekly, 150 mg monthly, or 5 mg daily 1, 2
Essential Supportive Measures
- Ensure total calcium intake of 1000-1200 mg/day (dietary plus supplementation if needed) and vitamin D 800 IU/day, targeting serum 25-OH vitamin D level ≥20 ng/mL 1, 2, 5
- Smoking cessation and limiting alcohol consumption are recommended 1, 2
Pre-Treatment Evaluation
- A dental screening examination is mandatory to identify and address any dental issues before starting bisphosphonate therapy, as bisphosphonates increase risk of osteonecrosis of the jaw, particularly with invasive dental procedures 6
- Check serum calcium level to exclude hypocalcemia (contraindication to bisphosphonate therapy) and assess renal function (creatinine clearance <35 mL/min is a contraindication to zoledronic acid) 1, 2
Monitoring Strategy
- Repeat DXA scan in 1-2 years to assess treatment response and continue monitoring every 1-2 years during treatment 7, 8
- Significant BMD change is ≥1.1% based on the facility's protocol 7
- Assess adherence and tolerance at regular intervals 3, 4